Strs Ohio Trims Stock Holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Strs Ohio decreased its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 14.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 16,000 shares of the company’s stock after selling 2,600 shares during the quarter. Strs Ohio’s holdings in Amphastar Pharmaceuticals were worth $989,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. McGlone Suttner Wealth Management Inc. purchased a new stake in Amphastar Pharmaceuticals in the fourth quarter worth about $28,000. Ronald Blue Trust Inc. increased its position in Amphastar Pharmaceuticals by 821.5% in the third quarter. Ronald Blue Trust Inc. now owns 1,198 shares of the company’s stock worth $55,000 after buying an additional 1,068 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in Amphastar Pharmaceuticals by 99.2% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,261 shares of the company’s stock worth $58,000 after buying an additional 628 shares in the last quarter. Covestor Ltd increased its position in Amphastar Pharmaceuticals by 859.0% in the third quarter. Covestor Ltd now owns 1,966 shares of the company’s stock worth $90,000 after buying an additional 1,761 shares in the last quarter. Finally, Nisa Investment Advisors LLC increased its position in Amphastar Pharmaceuticals by 115.0% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,430 shares of the company’s stock worth $150,000 after buying an additional 1,300 shares in the last quarter. Hedge funds and other institutional investors own 65.09% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Needham & Company LLC reiterated a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Wednesday, April 10th. JPMorgan Chase & Co. initiated coverage on Amphastar Pharmaceuticals in a research note on Tuesday, March 5th. They set an “overweight” rating and a $60.00 price target for the company. Finally, StockNews.com lowered Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, February 29th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, Amphastar Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $66.00.

Insider Transactions at Amphastar Pharmaceuticals

In related news, Director Michael A. Zasloff sold 12,500 shares of the company’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $47.18, for a total transaction of $589,750.00. Following the transaction, the director now directly owns 21,326 shares in the company, valued at approximately $1,006,160.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Director Floyd F. Petersen sold 500 shares of the company’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $53.10, for a total transaction of $26,550.00. Following the transaction, the director now directly owns 80,333 shares in the company, valued at approximately $4,265,682.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Michael A. Zasloff sold 12,500 shares of the company’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $47.18, for a total transaction of $589,750.00. Following the transaction, the director now owns 21,326 shares in the company, valued at $1,006,160.68. The disclosure for this sale can be found here. In the last quarter, insiders sold 14,000 shares of company stock worth $660,860. 27.10% of the stock is currently owned by insiders.

Amphastar Pharmaceuticals Price Performance

NASDAQ:AMPH opened at $40.91 on Wednesday. The firm has a market capitalization of $2.00 billion, a price-to-earnings ratio of 15.86, a PEG ratio of 0.95 and a beta of 0.85. The company has a debt-to-equity ratio of 0.92, a current ratio of 2.17 and a quick ratio of 1.70. The business has a 50 day simple moving average of $45.36 and a 200-day simple moving average of $51.09. Amphastar Pharmaceuticals, Inc. has a 1 year low of $35.62 and a 1 year high of $67.66.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings results on Wednesday, February 28th. The company reported $0.81 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.84 by ($0.03). The company had revenue of $178.11 million during the quarter, compared to the consensus estimate of $174.90 million. Amphastar Pharmaceuticals had a return on equity of 26.95% and a net margin of 21.34%. Equities analysts forecast that Amphastar Pharmaceuticals, Inc. will post 3.43 EPS for the current year.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.